Neurodermatitis Epidemiology Forecast 2025-2034

Neurodermatitis is estimated to affect 12% of the population, with women more likely to suffer from the condition than men. Studies show that people between the ages of 30 and 50 are susceptible to contracting neurodermatitis.

Neurodermatitis Epidemiology Forecast Report Coverage

The “Neurodermatitis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of neurodermatitis. It projects the future incidence and prevalence rates of neurodermatitis across various populations. The study covers age and type as major determinants of the neurodermatitis-affected population. The report highlights patterns in the prevalence of neurodermatitis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of neurodermatitis in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Neurodermatitis: Disease Overview

Neurodermatitis, also known as lichen simplex chronicus, is a chronic skin condition that causes thickened, itchy patches. It primarily affects adults and is often associated with a history of other dermatologic conditions. Neurodermatitis usually occurs in areas more prone to irritation, such as the neck, wrists, ankles, and genitals. Symptoms include dryness, intense itching, and thickened, leathery skin. Studies suggest that a combination of genetic predisposition, environmental triggers, and a heightened response to stress can make an individual susceptible to the condition.

Neurodermatitis: Treatment Overview

Topical corticosteroids are the most commonly prescribed medications to reduce inflammation and itching. They work by suppressing the immune system's inflammatory response. Topical calcineurin inhibitors like tacrolimus and pimecrolimus help reduce inflammation without the side effects of corticosteroids. Antihistamines are used to get relief from itching, especially if it's worsened by allergic reactions. Additionally, regular use of thick, fragrance-free moisturizers is also recommended to keep the skin hydrated.

Epidemiology

The neurodermatitis epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for neurodermatitis by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for neurodermatitis and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Approximately 12% of the population is estimated to be affected by neurodermatitis. It is also reported that people with family members with histories of other skin diseases, obsessive-compulsive disorders, and anxiety disorders are more likely to develop the condition.
• Around 1 in 8 people are affected by neurodermatitis. The patches associated with the condition range in size from 3 by 6 centimeters to 6 by 10 centimeters.
• Women are more likely to develop neurodermatitis than men, with research indicating that the condition affects women at a rate approximately twice as high as it does men, showing a 2:1 ratio.
• Lichen simplex chronicus, a common type of chronic neurodermatitis, typically develops in middle to late adulthood, with the highest occurrence seen in individuals between the ages of 30 and 50.

Country-wise Neurodermatitis Epidemiology

The neurodermatitis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of neurodermatitis varies significantly between countries due to differences in genetic factors, environmental influences, healthcare access, and diagnostic practices. About 31.6 million people in the United States, or 10.1% of the population, are affected by some form of eczema including neurodermatitis.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of neurodermatitis based on several factors.
• The Neurodermatitis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of neurodermatitis are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of neurodermatitis epidemiology in the 8 major markets?
• What will be the total number of patients with neurodermatitis across the 8 major markets during the forecast period?
• What was the country-wise prevalence of neurodermatitis in the 8 major markets in the historical period?
• Which country will have the highest number of neurodermatitis patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of neurodermatitis during the forecast period of 2025-2034?
• What are the currently available treatments for neurodermatitis?
• What are the disease risks, signs, symptoms, and unmet needs of neurodermatitis?

This product will be delivered within 3-5 business days.